Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

CMC and Bioprocess Blog

Execution-focused articles on CMC strategy, bioprocess scale-up, tech transfer, CDMO selection, and GMP readiness for process development scientists and manufacturing leaders scaling biologics into regulatory-ready therapies.

Uncategorized

Today we’re diving into something that could literally save your company from becoming another biotech statistic.

Bioprocessing

What happens when the charging elephant of biotech—antibody-drug conjugates (ADCs)—meets the organizational complexity of a 300-strong analytical powerhouse?

Bioprocessing

Antibody-drug conjugates (ADCs) are generating serious buzz in biotech corridors, offering a precision-guided missile against cancer while minimizing collateral damage.

Bioprocessing

A common misconception among many researchers and biotech startup founders is that bioprocess development is straightforward.

Innovation

The world of medicine stands on the precipice of a new era.

Biotech Success

What’s the single most formidable hurdle for a promising biotech breakthrough? It’s crafting a robust CMC (Chemistry, Manufacturing, and Controls) strategy.

Bioprocessing

Bioprocess development demands a careful blend of biology, engineering, and strategic planning.

Bioprocessing

Biotech processes hinge on delivering sufficient oxygen to growing cells in a bioreactor.

Data & Analytics

What does it take to crack the code of protein production—and why do some proteins stubbornly refuse to cooperate, despite the best efforts of scientists and engineers?

Data & Analytics

Somewhere in your lab, a hard drive is quietly storing omics data that hasn’t seen the light of day in years—genome sequences, metabolomics runs, scribbled notes in aging ELNs.

Data & Analytics

Leveraging digital models and AI-powered tools can make all the difference for both R&D and manufacturing, but finding the right starting point—and justifying the investment—can feel overwhelming.

Data & Analytics

Is your bioprocess development stacked with siloed data, endless spreadsheets, and a constant battle to identify where to start your digital transformation?

Data & Analytics

What separates labs with truly connected, AI-ready data from those drowning in digital chaos?

Data & Analytics

What if the real bottleneck in biotech labs isn’t equipment, talent, or even funding—but a silent issue lurking in plain sight: fragmented data?

Biotech Success

How do you know when your biotech startup is ready to sell—before the product is “perfect”?

Biotech Success

Most bioprocess innovation is dismissed as a “fool’s game”—until the skeptics are proven wrong.

Biotech Success

What happens when the solution to America’s insulin crisis isn’t a new molecule or fancy delivery device—but a new way of thinking about biotech itself?

Biotech Success

What if affordable insulin isn’t a scientific hurdle—but a financial and distribution puzzle no one’s been motivated to solve?

Biotech Success

Securing capital for biotech innovation has never been more challenging—or more crucial.

Biotech Success

Strong science alone won’t get your biotech startup funded—investors are sizing up much more than just your molecule.

Innovation

Hard-to-treat cancers like pancreatic ductal adenocarcinoma have defied conventional therapies for decades.

Innovation

Imagine treating cancer with something as precise as a guided missile—radioactive payloads delivered only where they’re needed most.

Innovation

What happens when you stop settling for oversimplified cell cultures and start reimagining how we decode the complexity of tumors, immunotherapies, and gene therapies?

Innovation

Ever wondered what actually happens to human cells when you scale up bioprocessing from a petri dish to a bioreactor?

Innovation

For generations, silkworm pupae were simply a byproduct of silk spinning.

Innovation

Could silkworms—yes, those iconic contributors to silk—hold the key to the next leap in vaccine and protein manufacturing?

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.

No spam. Unsubscribe anytime.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.


No spam. Unsubscribe anytime.